Shandong Weigao Group Medical Polymer Company Limited (01066) announced a Next Day Disclosure Return dated 16 February 2026, detailing recent share repurchase activity and changes in its issued share structure. The opening balance of issued shares (excluding treasury shares) stood at 4.48 billion as of 13 February 2026, with 4.52 billion shares in total when treasury shares are included. After a repurchase on 16 February 2026, the closing balance of issued shares (excluding treasury shares) was 4.48 billion, while treasury shares rose to 41.46 million, keeping the total unchanged at 4.52 billion.

On 16 February 2026, 62,000 H shares were repurchased at a volume-weighted average price of HKD 5.10 per share, for a total payment of HKD 315,920. None of these repurchased shares were cancelled; all were held as treasury shares. According to the repurchase mandate dated 27 May 2025, Shandong Weigao is authorized to repurchase up to 451.56 million shares; to date, 34.81 million shares (representing about 7.71% of the issued shares at the time the mandate was granted) have been repurchased. Under the rules, no new shares or treasury shares may be issued, sold, or transferred until 19 March 2026 unless prior approval is obtained.